Skip to main content
Top
Published in: Calcified Tissue International 5/2013

01-11-2013 | Original Research

Comparable Effects of Alendronate and Strontium Ranelate on Femur in Ovariectomized Rats

Authors: BaiLing Chen, YiQiang Li, XiaoXi Yang, DengHui Xie

Published in: Calcified Tissue International | Issue 5/2013

Login to get access

Abstract

This study compared the effects of alendronate (ALN) and strontium ranelate (SR) on bone mineral density (BMD), bone histomorphometry, and biomechanics in ovariectomized (OVX) rats. We randomly assigned 48 3-month-old female Sprague–Dawley rats to four groups: sham, OVX, ALN, and SR. Rats in the OVX, ALN, and SR groups received bilateral OVX. Rats in the ALN and SR groups were orally administrated ALN (7 mg/kg/week) and SR (500 mg/kg/day). Rats in the sham and OVX groups were treated with saline. All treatments continued for 12 weeks. Femoral BMD examination, distal femoral bone histomorphometry analysis, and biomechanical tests at the femoral diaphysis and metaphysis were performed to evaluate the effects of treatments in OVX rats. Results showed that both ALN and SR significantly increased femoral BMD (total femur, diaphyseal BMD, and distal metaphyseal BMD), distal femoral bone histomorphometric parameters (BV/TV, Tb.N, and Tb.Th), and femoral biomechanical parameters (maximum load, failure load, stiffness) compared with the OVX group (P < 0.05). No differences were found between ALN and SR in increasing femoral BMD, distal femoral bone histomorphometric parameters (BV/TV, Tb.N, and Tb.Th), and femoral diaphysis biomechanical parameters (maximum load, failure load, stiffness) (P > 0.05). The SR group was inferior to the ALN group in femoral metaphysis biomechanical parameters (P < 0.05). In conclusion, ALN (7 mg/kg/week) and SR (500 mg/kg/day) have similar effects by increasing BMD, distal femoral bone histomorphometric parameters, and femoral metaphysis biomechanical properties. Although ALN has greater effects than SR on distal femoral metaphysis biomechanical properties, in general, ALN and SR have comparable effects on the femur in OVX rats.
Literature
1.
2.
go back to reference Iacono MV (2007) Osteoporosis: a national public health priority. J Perianesth Nurs 22(3):175–182PubMedCrossRef Iacono MV (2007) Osteoporosis: a national public health priority. J Perianesth Nurs 22(3):175–182PubMedCrossRef
3.
go back to reference North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 17(1):25–54CrossRef North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 17(1):25–54CrossRef
4.
go back to reference Christenson ES, Jiang X, Kagan R, Schnatz P (2012) Osteoporosis management in post-menopausal women. Minerva Ginecol 64(3):181–194PubMed Christenson ES, Jiang X, Kagan R, Schnatz P (2012) Osteoporosis management in post-menopausal women. Minerva Ginecol 64(3):181–194PubMed
5.
go back to reference Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86(11):1022–1033PubMedCrossRef Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86(11):1022–1033PubMedCrossRef
6.
go back to reference Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199CrossRef Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199CrossRef
7.
go back to reference Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20(1):141–151CrossRef Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20(1):141–151CrossRef
8.
go back to reference Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the fracture intervention trial. J Bone Miner Res 27(8):1804–1810PubMedCrossRef Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the fracture intervention trial. J Bone Miner Res 27(8):1804–1810PubMedCrossRef
9.
go back to reference Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44(6):1078–1084PubMedCrossRef Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44(6):1078–1084PubMedCrossRef
10.
11.
go back to reference Marie PJ (2005) Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int 16(Suppl 1):S7–S10PubMedCrossRef Marie PJ (2005) Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int 16(Suppl 1):S7–S10PubMedCrossRef
12.
go back to reference Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42(1):129–138PubMedCrossRef Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42(1):129–138PubMedCrossRef
13.
go back to reference Ma YL, Zeng QQ, Porras LL, Harvey A, Moore TL, Shelbourn TL, Dalsky GP, Wronski TJ, Aguirre JI, Bryant HU, Sato M (2011) Teriparatide [rhPTH(1–34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology 152(5):1767–1778PubMedCrossRef Ma YL, Zeng QQ, Porras LL, Harvey A, Moore TL, Shelbourn TL, Dalsky GP, Wronski TJ, Aguirre JI, Bryant HU, Sato M (2011) Teriparatide [rhPTH(1–34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology 152(5):1767–1778PubMedCrossRef
14.
go back to reference Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Phipps RJ, Burr DB (2008) Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19(9):1331–1341PubMedCrossRef Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Phipps RJ, Burr DB (2008) Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19(9):1331–1341PubMedCrossRef
15.
go back to reference Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate–induced osteoblast proliferation. Biochem Pharmacol 74(3):438–447PubMedCrossRef Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate–induced osteoblast proliferation. Biochem Pharmacol 74(3):438–447PubMedCrossRef
16.
go back to reference Caverzasio J (2008) Strontium ranelate promotes osteoblast cell replication through at least two different mechanisms. Bone 42(6):1131–1136PubMedCrossRef Caverzasio J (2008) Strontium ranelate promotes osteoblast cell replication through at least two different mechanisms. Bone 42(6):1131–1136PubMedCrossRef
17.
go back to reference Pi M, Quarles LD (2004) A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res 19(5):862–869PubMedCrossRef Pi M, Quarles LD (2004) A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res 19(5):862–869PubMedCrossRef
18.
go back to reference Atkins GJ, Welldon KJ, Halbout P, Findlay DM (2009) Strontium ranelate treatment of primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20:653–664PubMedCrossRef Atkins GJ, Welldon KJ, Halbout P, Findlay DM (2009) Strontium ranelate treatment of primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20:653–664PubMedCrossRef
19.
go back to reference Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157(7):1291–1300PubMedCrossRef Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157(7):1291–1300PubMedCrossRef
20.
go back to reference Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468PubMedCrossRef Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468PubMedCrossRef
21.
go back to reference Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822PubMedCrossRef Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822PubMedCrossRef
22.
go back to reference Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos Int 22(8):2347–2355PubMedCrossRef Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos Int 22(8):2347–2355PubMedCrossRef
23.
go back to reference Liu JM, Wai-Chee Kung A, Pheng CS, Zhu HM, Zhang ZL, Wu YY, Xu L, Meng XW, Huang ML, Chung LP, Hussain NH, Sufian SS, Chen JL (2009) Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis. Bone 45(3):460–465PubMedCrossRef Liu JM, Wai-Chee Kung A, Pheng CS, Zhu HM, Zhang ZL, Wu YY, Xu L, Meng XW, Huang ML, Chung LP, Hussain NH, Sufian SS, Chen JL (2009) Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis. Bone 45(3):460–465PubMedCrossRef
24.
go back to reference Rizzoli R, Laroche M, Krieg MA, Frieling I, Thomas T, Delmas P, Felsenberg D (2010) Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 30(10):1341–1348PubMedCrossRef Rizzoli R, Laroche M, Krieg MA, Frieling I, Thomas T, Delmas P, Felsenberg D (2010) Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 30(10):1341–1348PubMedCrossRef
25.
go back to reference Rizzoli R, Chapurlat RD, Laroche JM, Krieg MA, Thomas T, Frieling I, Boutroy S, Laib A, Bock O, Felsenberg D (2012) Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int 23(1):305–315PubMedCrossRef Rizzoli R, Chapurlat RD, Laroche JM, Krieg MA, Thomas T, Frieling I, Boutroy S, Laib A, Bock O, Felsenberg D (2012) Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int 23(1):305–315PubMedCrossRef
26.
go back to reference Sun P, Cai DH, Li QN, Chen H, Deng WM, He L, Yang L (2010) Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats. Calcif Tissue Int 86(6):495–501PubMedCrossRef Sun P, Cai DH, Li QN, Chen H, Deng WM, He L, Yang L (2010) Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats. Calcif Tissue Int 86(6):495–501PubMedCrossRef
27.
go back to reference National Research Council, Committee for the Update of the Guide for the Care and Use of Laboratory Animals (2011) Guide for the care and use of laboratory animals, 8th edn. National Academies, USA National Research Council, Committee for the Update of the Guide for the Care and Use of Laboratory Animals (2011) Guide for the care and use of laboratory animals, 8th edn. National Academies, USA
28.
go back to reference Chen BL, Li YQ, Xie DH, Yang XX (2012) Low-magnitude high-frequency loading via whole body vibration enhances bone implant osseointegration in ovariectomized rats. J Orthop Res 30(5):733–739PubMedCrossRef Chen BL, Li YQ, Xie DH, Yang XX (2012) Low-magnitude high-frequency loading via whole body vibration enhances bone implant osseointegration in ovariectomized rats. J Orthop Res 30(5):733–739PubMedCrossRef
29.
go back to reference Chen B, Li Y, Yang X, Xie D (2012) Femoral metaphysis bending test of rat: introduction and validation of a novel biomechanical testing protocol for osteoporosis. J Orthop Sci 17(1):70–76PubMedCrossRef Chen B, Li Y, Yang X, Xie D (2012) Femoral metaphysis bending test of rat: introduction and validation of a novel biomechanical testing protocol for osteoporosis. J Orthop Sci 17(1):70–76PubMedCrossRef
30.
go back to reference Sliwiński L, Janiec W, Pytlik M, Folwarczna J, Kaczmarczyk-Sedlak I, Pytlik W, Cegieła U, Nowińska B (2004) Effect of administration of alendronate sodium and retinol on the mechanical properties of the femur in ovariectomized rats. Pol J Pharmacol 56(6):817–824PubMed Sliwiński L, Janiec W, Pytlik M, Folwarczna J, Kaczmarczyk-Sedlak I, Pytlik W, Cegieła U, Nowińska B (2004) Effect of administration of alendronate sodium and retinol on the mechanical properties of the femur in ovariectomized rats. Pol J Pharmacol 56(6):817–824PubMed
31.
go back to reference Seedor JG, Quartuccio HA, Thompson DD (1991) The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. Bone Miner Res 6(4):339–346CrossRef Seedor JG, Quartuccio HA, Thompson DD (1991) The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. Bone Miner Res 6(4):339–346CrossRef
32.
go back to reference Wang Y, Huang P, Tang PF, Chan KM, Li G (2011) Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. J Orthop Surg Res 6:34PubMedCrossRef Wang Y, Huang P, Tang PF, Chan KM, Li G (2011) Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. J Orthop Surg Res 6:34PubMedCrossRef
33.
go back to reference Ahmet-Camcioglu N, Okman-Kilic T, Durmus-Altun G, Ekuklu G, Kucuk M (2009) Effects of strontium ranelate, raloxifene and misoprostol on bone mineral density in ovariectomized rats. Eur J Obstet Gynecol Reprod Biol 147(2):192–194PubMedCrossRef Ahmet-Camcioglu N, Okman-Kilic T, Durmus-Altun G, Ekuklu G, Kucuk M (2009) Effects of strontium ranelate, raloxifene and misoprostol on bone mineral density in ovariectomized rats. Eur J Obstet Gynecol Reprod Biol 147(2):192–194PubMedCrossRef
34.
go back to reference Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20(8):1417–1428PubMedCrossRef Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20(8):1417–1428PubMedCrossRef
35.
go back to reference Ulrich U, Miller P, Eyre D, Chesnut CR, Schlebusch H, Soules M (2003) Bone remodeling and bone mineral density during pregnancy. Arch Gynecol Obstet 268:309–316PubMedCrossRef Ulrich U, Miller P, Eyre D, Chesnut CR, Schlebusch H, Soules M (2003) Bone remodeling and bone mineral density during pregnancy. Arch Gynecol Obstet 268:309–316PubMedCrossRef
36.
go back to reference Chachra D, Lee JM, Kasra M, Grynpas MD (2000) Differential effects of ovariectomy on the mechanical properties of cortical and cancellous bone in rat femora and vertebrae. Biomed Sci Instrum 36:123–128PubMed Chachra D, Lee JM, Kasra M, Grynpas MD (2000) Differential effects of ovariectomy on the mechanical properties of cortical and cancellous bone in rat femora and vertebrae. Biomed Sci Instrum 36:123–128PubMed
37.
go back to reference Thongchote K, Charoenphandhu N, Krishnamra N (2008) High physiological prolactin induced by pituitary transplantation decreases BMD and BMC in the femoral metaphysis, but not in the diaphysis of adult female rats. J Physiol Sci 58:39–45PubMedCrossRef Thongchote K, Charoenphandhu N, Krishnamra N (2008) High physiological prolactin induced by pituitary transplantation decreases BMD and BMC in the femoral metaphysis, but not in the diaphysis of adult female rats. J Physiol Sci 58:39–45PubMedCrossRef
38.
go back to reference Yaffe A, Kollerman R, Bahar H, Binderman I (2003) The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. J Periodontol 74(1):44–50PubMedCrossRef Yaffe A, Kollerman R, Bahar H, Binderman I (2003) The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. J Periodontol 74(1):44–50PubMedCrossRef
39.
go back to reference Nijenhuis T, van der Eerden BC, Hoenderop JG, Weinans H, van Leeuwen JP, Bindels RJ (2008) Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5−/− mice. J Bone Miner Res 23(11):1815–1824PubMedCrossRef Nijenhuis T, van der Eerden BC, Hoenderop JG, Weinans H, van Leeuwen JP, Bindels RJ (2008) Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5−/− mice. J Bone Miner Res 23(11):1815–1824PubMedCrossRef
Metadata
Title
Comparable Effects of Alendronate and Strontium Ranelate on Femur in Ovariectomized Rats
Authors
BaiLing Chen
YiQiang Li
XiaoXi Yang
DengHui Xie
Publication date
01-11-2013
Publisher
Springer US
Published in
Calcified Tissue International / Issue 5/2013
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-013-9765-z

Other articles of this Issue 5/2013

Calcified Tissue International 5/2013 Go to the issue